ERBB2 and gastric cancer: Despite improvements, targeted therapies have proved disappointing in GC [4], and those approved (trastuzumab against HER2, ramucirumab against VEGFR2, and pembrolizumab against PDL1) show yet limited OS improvement [4,5,6].